Logo image
Back
Inflammatory Markers and Outcomes After Lacunar Stroke: Levels of Inflammatory Markers in Treatment of Stroke Study
Journal article   Open access   Peer reviewed

Inflammatory Markers and Outcomes After Lacunar Stroke: Levels of Inflammatory Markers in Treatment of Stroke Study

Amelia K Boehme, Leslie A McClure, Yu Zhang, Jorge M Luna, Oscar H Del Brutto, Oscar R Benavente and Mitchell S V Elkind
Stroke (1970), v 47(3), pp 659-667
Mar 2016
DOI: https://doi.org/10.1161/STROKEAHA.115.012166
PMID: 26888535
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1161/strokeaha.115.012166View
Published, Version of Record (VoR)Maybe Open Access (Publisher Bronze),  Open
url
https://doi.org/10.1161/STROKEAHA.115.012166View
Published, Version of Record (VoR) Open

Abstract

Aged Biomarkers - blood Female Humans Inflammation Mediators - blood Interleukin-6 - blood Male Middle Aged Platelet Aggregation Inhibitors - administration & dosage Prospective Studies Receptors, Tumor Necrosis Factor, Type I - blood Risk Factors Stroke, Lacunar - blood Stroke, Lacunar - diagnosis Stroke, Lacunar - drug therapy Treatment Outcome
We hypothesized that concentrations of interleukin 6 (IL-6), serum amyloid A, tumor necrosis factor-α receptor 1, CD40 ligand, and monocyte chemoattractant protein 1 would predict recurrent ischemic stroke and major vascular events after recent lacunar stroke. Levels of Inflammatory Markers in the Treatment of Stroke (LIMITS) was an international, multicenter, prospective ancillary biomarker study nested within the Secondary Prevention of Small Subcortical Strokes (SPS3) study, a Phase III trial in patients with recent lacunar stroke. Crude and Adjusted Cox proportional hazards models were used to calculate hazard ratios (HRs) and 95% confidence intervals (95% CI) for recurrence risks. Among 1244 patients with lacunar stroke (mean age, 63.3±10.8 years), there were 115 major vascular events (stroke, myocardial infarction, and vascular death). The risk of major vascular events increased with elevated concentrations of both tumor necrosis factor-α receptor 1 (adjusted HR per SD, 1.21; 95% CI, 1.05-1.41; P=0.01) and IL-6 (adjusted HR per SD, 1.10; 95% CI, 1.02-1.19; P=0.008). Compared with the bottom quartile (tumor necrosis factor-α receptor 1 <2.24 ng/L), those in the top quartile of tumor necrosis factor-α receptor 1 (>3.63 ng/L) were at twice the risk of major vascular events after adjusting for demographics (partially adjusted HR, 1.98; 95% CI, 1.11-3.52), though the effect attenuated after adjusting for other risk factors and statin use (adjusted HR, 1.68; 95% CI, 0.93-3.04). Serum amyloid A, CD40 ligand, and monocyte chemoattractant protein 1 were not associated with prognosis. Among recent lacunar stroke patients, IL-6 and TNF receptor concentrations predict risk of recurrent vascular events, and they are associated with the effect of antiplatelet therapies. URL: http://www.clinicaltrials.gov. Unique identifier: NCT00059306.

Metrics

13 Record Views
88 citations in Web of Science
87 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
International collaboration
Web of Science research areas
Clinical Neurology
Peripheral Vascular Disease
Logo image